ADVFN Logo ADVFN

No pudimos encontrar ningún resultado para:
Asegúrate de que la ortografía sea correcta o intenta ampliar tu búsqueda.

Tendencias Ahora

Listas Principales

Parece que no has iniciado sesión.
Haz clic en el botón de abajo para iniciar sesión y ver tu historial reciente.

Regístrate

¿Ya eres miembro? Iniciar sesión

Los Principales Corredores en Línea

Más Corredores en Línea

Datos
Noticias
Herramientas
Mercados
Descubrir

Hot Features

Follow Feed

Conéctese con traders e inversores en nuestra comunidad Follow Feed.

Flujo de Opciones

Explora datos de opciones completos y utiliza filtros avanzados con Options Flow.

Monitor

Organiza y monitorea tu lista de seguimiento de acciones y activos con Monitor.
Iniciar Sesión Premium IconPremium Help Menu
S&P 500
5,459.10
1.11%
Dow Jones
40,589.34
1.64%
US Dollar vs MXN
18.44836
0.03%
Brent Oil
79.955
-0.77%
Bitcoin
69,778.21
2.92%
Registration Strip Icon for alerts Regístrate para obtener alertas en tiempo real, cartera personalizada y movimientos del mercado.
Regístrate
  1. Inicio
  2. Invertir
  3. Acciones
  4. Estados Unidos
  5. NASDAQ

  6. Lipella Pharmaceuticals Inc (LIPO) Cotización

Lipella Pharmaceuticals Inc

Lipella Pharmaceuticals Inc (LIPO)

NASDAQ
0.4041
0.0091
(2.30%)
Cerrado 26 Julio 3:00PM
Delayed by 15 minutes
0.7463
0.3422
( 84.68% )
Pre Mercado: 6:11AM
Delayed by 15 minutes

Su centro para precios en tiempo real, ideas y debates en vivo

Premium

Estadísticas y detalles clave

Último Precio
0.7463
Postura de Compra
0.7455
Postura de Venta
0.75
Volume Operado de la Acción
13,586,149
0.00 Rango del Día 0.00
0.3611 Rango de 52 semanas 2.71
Capitalización de Mercado [m]
5.676M
Precio Anterior
0.4041
Precio de Apertura
-
Hora
135
@
0.7463
(formt)
Última hora de negociación
06:11:17
Volumen financiero
-
Precio Promedio Ponderado
-
Volumen promedio (3 m)
47,360
Acciones en circulación
7,605,636
Rendimiento del Dividendo
-
Ratio Precio/Utilidad
-0.66
Beneficio por acción (BPA)
-0.61
turnover
450k
Beneficio neto
-4.62M

Acerca de Lipella Pharmaceuticals Inc

Lipella Pharmaceuticals Inc., a clinical-stage biotechnology company, focuses on developing drugs by reformulating the active agents in existing generic drugs and optimizing these reformulations for various applications. It is developing LP-10, a formulation of tacrolimus that is in Phase IIa clinic... Lipella Pharmaceuticals Inc., a clinical-stage biotechnology company, focuses on developing drugs by reformulating the active agents in existing generic drugs and optimizing these reformulations for various applications. It is developing LP-10, a formulation of tacrolimus that is in Phase IIa clinical trial for patients with radiation-induced hemorrhagic cystitis; and LP-310, a formulation of tacrolimus for the treatment of oral lichen planus. Lipella Pharmaceuticals Inc. was incorporated in 2005 and is based in Pittsburgh, Pennsylvania. Mostrar más

Sector
Pharmaceutical Preparations
Industria
Pharmaceutical Preparations
Sitio web
www.lipella.com
Sede
Wilmington, Delaware, USA
Fundado
1970
Lipella Pharmaceuticals Inc is listed in the Pharmaceutical Preparations sector of the NASDAQ with ticker LIPO. The last closing price for Lipella Pharmaceuticals was US$0.40. Over the last year, Lipella Pharmaceuticals shares have traded in a share price range of US$ 0.3611 to US$ 2.71.

Lipella Pharmaceuticals currently has 7,605,636 shares in issue. The market capitalisation of Lipella Pharmaceuticals is US$3.07 million. Lipella Pharmaceuticals has a price to earnings ratio (PE ratio) of -0.66.

LIPO Últimas noticias

Más noticias

Lipella Pharmaceuticals Initiates Phase 2a Trial for LP-310 in Oral Lichen Planus, Enrolls First Patients

PITTSBURGH, July 29, 2024 (GLOBE NEWSWIRE) -- Lipella Pharmaceuticals Inc. (Nasdaq: LIPO) (“Lipella” or the “Company”), a clinical-stage biotechnology company addressing serious diseases with...

2 horas hace
GlobeNewswire Inc.

Lipella Pharmaceuticals Announces Completion of Site Initiation Visit for Phase 2a Trial of LP-310 in Oral Lichen Planus

Clinical testing of LP-310 expected to commence in mid-2024 Patient recruitment is underway for Phase 2a multicenter, dose-ranging study PITTSBURGH, May 31, 2024 (GLOBE NEWSWIRE) -- Lipella...

31 Mayo 2024
GlobeNewswire Inc.

Lipella Pharmaceuticals Announces Abstract Publication at 2024 American Society of Clinical Oncology (ASCO) Annual Meeting

PITTSBURGH, May 29, 2024 (GLOBE NEWSWIRE) -- Lipella Pharmaceuticals Inc. (Nasdaq: LIPO) (“Lipella,” “our,” “us” or the “Company”), a clinical-stage biotechnology company addressing serious...

29 Mayo 2024
GlobeNewswire Inc.

Following Guidance from U.S. Food & Drug Administration in Type-C Meeting Lipella Pharmaceuticals to Advance Lead Product Candidate to Phase 2b

PITTSBURGH, May 21, 2024 (GLOBE NEWSWIRE) -- Lipella Pharmaceuticals Inc. (NASDAQ: LIPO) (“Lipella” or the “Company”), a clinical-stage biotechnology company, announced today the receipt of U.S...

21 Mayo 2024
GlobeNewswire Inc.

Form 4 - Statement of changes in beneficial ownership of securities

15 Mayo 2024
Edgar (US Regulatory)

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

09 Mayo 2024
Edgar (US Regulatory)

Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend]

06 Mayo 2024
Edgar (US Regulatory)

Lipella Pharmaceuticals Expands its Advisory Board to Include Oncology Expertise

PITTSBURGH, Pa., April 17, 2024 (GLOBE NEWSWIRE) -- Lipella Pharmaceuticals Inc. (Nasdaq: LIPO) (“Lipella” or the “Company”), a clinical-stage biotechnology company, today announced the...

17 Abril 2024
GlobeNewswire Inc.

Lipella Pharmaceuticals to Publish Abstract Detailing Compelling Preclinical Support for New Product Candidate at ASCO 2024

PITTSBURGH, April 05, 2024 (GLOBE NEWSWIRE) -- Lipella Pharmaceuticals Inc. (NASDAQ: LIPO) (“Lipella,” “our”, “us” or the “Company”), a clinical-stage biotechnology company addressing serious...

05 Abril 2024
GlobeNewswire Inc.

Lipella Pharmaceuticals Announces FDA Type C Meeting for LP-10 for Hemorrhagic Cystitis

PITTSBURGH, April 03, 2024 (GLOBE NEWSWIRE) -- Lipella Pharmaceuticals Inc. (Nasdaq: “LIPO”) (“Lipella,” “our,” “us” or the “Company”), a clinical-stage biotechnology company addressing serious...

03 Abril 2024
GlobeNewswire Inc.
Período †Variación(Ptos)Variación %AperturaPrecio MáximoPrecio MínimoAvg. Vol. diarioPrecio Promedio Ponderado
10.28762.48639233620.45930.46750.3611610460.4178952CS
40.267355.80375782880.4790.5750.3611591680.47669928CS
120.00871.17950108460.73760.7880.3611473600.56739499CS
26-0.3137-29.59433962261.061.30.3611525850.71519754CS
52-1.3337-64.12019230772.082.710.36112249891.90587248CS
156-6.2737-89.36894586897.027.720.36112949082.48163216CS
260-6.2737-89.36894586897.027.720.36112949082.48163216CS

Movimientos

Ver todo
  • Volumen
  • % Mayores Alzas
  • % Mayores Bajas
SímboloPrecioVol.
YIBOPlanet Image International Ltd
US$ 4.93
(69.13%)
3.16M
LIPOLipella Pharmaceuticals Inc
US$ 0.6559
(62.31%)
10.88M
CGTXCognition Therapeutics Inc
US$ 3.43
(44.73%)
1.71M
TIVCTivic Health Systems Inc
US$ 0.64
(41.59%)
2.8M
LGVNLongeveron Inc
US$ 4.25
(23.55%)
3.57M
VTVTvTv Therapeutics Inc
US$ 11.78
(-44.43%)
5.75k
CEROCERo Therapeutics Holdings Inc
US$ 0.174
(-32.03%)
547.39k
TGLTreasure Global Inc
US$ 1.38
(-25.41%)
5.07k
LUXHLuxUrban Hotels Inc
US$ 0.1588
(-16.86%)
119.6k
IARTIntegra LifeSciences Holdings Corporation
US$ 27.00
(-14.09%)
861
LIPOLipella Pharmaceuticals Inc
US$ 0.6572
(62.63%)
10.88M
LGVNLongeveron Inc
US$ 4.25
(23.55%)
3.57M
BFIBurgerFi International Inc
US$ 0.51
(21.28%)
3.29M
YIBOPlanet Image International Ltd
US$ 4.93
(69.13%)
3.16M
TIVCTivic Health Systems Inc
US$ 0.64
(41.59%)
2.8M

LIPO Discussion

Ver más
FALCON1 FALCON1 2 días hace
https://www.zacks.com/stock/news/2300964/the-zacks-analyst-blog-highlights-danaher-morgan-stanley-pfizer-elite-pharmaceuticals-and-oil-dri

https://www.zacks.com/stock/news/2300922/zacks-initiates-coverage-of-elite-pharmaceuticals-with-outperform-recommendation
👍️0
oldstocks oldstocks 5 meses hace
You made me feel old, then i remembered my grandchildren
541,000 LIPO shares traded down 1.9%
Wow normally low volume
J A G X had a lot of volume too 380 mill
Pharmaceuticals are hot
👍️0
Muhbruh Muhbruh 5 meses hace
$LIPO Bio with nice bottom chart 6.6m float, 10 months of cash Insiders own 36% Warrants at $1.40 last offering was at $1.52 and has Upcoming catalyst pic.twitter.com/2j5I3G9MTE— STOCKS Gambino (@StocksGambino) March 4, 2024
👍️0
Monksdream Monksdream 5 meses hace
Roll the dice, gramps you can’t take it with you
👍️0
oldstocks oldstocks 5 meses hace
This doesn’t trade many shares.
Volume is coming
👍️0
Monksdream Monksdream 5 meses hace
LIPO under $2
👍️0
crudeoil24 crudeoil24 9 meses hace
Heading to FDA phase II trial. Long ways to go before FDA phase III approval for marketplace.
👍️0
crudeoil24 crudeoil24 9 meses hace
Shares of Lipella Pharmaceuticals Inc. (LIPO) rocketed 52.2% higher in very active tracing Friday, after the Pittsburgh-based biotechnology company's investigational new drug application for its oral lichen planus treatment was approved by the U.S. Food and Drug Administration. Trading volume in the stock, which was the best performer on the major U.S. exchanges, blasted higher to 30.7 million shares, compared with the full-day average of about 6,400 shares. The stock has soared 150% in the three days since it last closed below the $1 mark, and has run up 164% amid a six-day winning streak. as Lipella described, OLP is a chronic, inflammatory autoimmune oral muscosal disease. It is a "highly morbid" condition with malignant potential that affects between 1% and 4% of the world population. Lipella's stock has now gained 18.6% over the past three months, but was still 57% below its initial public offering price of $5.75; the company went public on Dec. 20.

-Tomi Kilgore

For more from MarketWatch: http://www.marketwatch.com/newsviewer
👍️0
Monksdream Monksdream 9 meses hace
Early Barchart Top 100
https://www.barchart.com/stocks/performance/percent-change/advances?orderBy=percentChange&orderDir=desc
👍️0
Awl416 Awl416 9 meses hace
Lipella Pharmaceuticals Announces FDA Clearance of IND for LP-310 for Oral Lichen Planus
👍️0
MiamiGent MiamiGent 1 año hace
That's it for me, folks!
Went much longer than usual but I have had a terrific day-following a bad day yesterday.
Hit on LIPO news today. Was positioned for the good pop. What a difference a day can make!
Have to drive across the mountain, now. Go do inventory at a shop open late. Then deliver there tomorrow.

LIPO Quote
AS OF 3/16/2023 3:16PM ET

$2.54
+$0.71 (+38.798%)

Volume
22,990,230
90 Day Avg. Vol.
564,085
Open
$2.77
Previous Close 03/15/2023
$1.83

https://stockcharts.com/h-sc/ui?s=LIPO
👍️0
TheFinalCD TheFinalCD 1 año hace
LIPO NEWS https://finance.yahoo.com/news/lipella-pharmaceuticals-successfully-completes-phase-123000776.html


Hemorrhagic cystitis is a medical condition that occurs when your urinary bladder lining becomes inflamed and bleeds. Your bladder is a muscular sac in your pelvis that stores urine before it's released from your body. Hemorrhagic means bleeding, and cystitis is inflammation of the bladder
👍️0
81vette 81vette 1 año hace
Lipella Pharmaceuticals’ (NASDAQ:LIPO – Get Rating) quiet period will expire on Monday, January 30th. Lipella Pharmaceuticals had issued 1,217,391 shares in its IPO on December 20th. The total size of the offering was $6,999,998 based on an initial share price of $5.75. During Lipella Pharmaceuticals’ quiet period, insiders and underwriters involved in the IPO are prevented from issuing any research reports or earnings estimates for the company because of regulations issued by the Securities and Exchange Commission. Following the end of the company’s quiet period, it’s expected that the brokerages that served as underwriters on the stock will initiate research coverage on the company.
👍️0
81vette 81vette 1 año hace
65,502 failure to deliver from 1-13 ,wow $300,000@$3.00pps ,insane margin call,shorts better cover now,at ask would put LIPO over $100pps right now ,set my sell at $150.00 just in case
👍️0
81vette 81vette 1 año hace
.05 spread,jumping .10-.50 today,no toxic debt or naked short on this newie,after market and pre-mkt tomorrow could gap LIPO multi$,gotta love low float newies
👍️0
81vette 81vette 1 año hace
35Xs ave vol,big pre mkt today 1st sign of life since ticker started,now gap filled,charting predictable,appears something coming and float locked up @zero/restricted borrow,436% fee
👍️0
81vette 81vette 1 año hace
zero borrow,no shares to short,squeeze em babe!!!!
👍️0
81vette 81vette 1 año hace
Shares Outstanding 5.74M,Shares Float 3.77M,Institutional Ownership 6.96%,Insider Ownership 34.42%,Short Float 6.25%, 235,322 shares short
👍️0
MegaDeath MegaDeath 1 año hace
LIPO, Nice day here so far. Thanks for the heads up Hanibal.
👍️0
makinezmoney makinezmoney 1 año hace
$LIPO: Niceeeeeeeeee bounce here....... now 3.80


Came off the bottom.................. nice mercy bounce there from $3 at the open

GO $LIPO
👍️0

Su Consulta Reciente

NASDAQ
LIPO
Lipella Pharmaceuticals
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

México
Empresa
Negocios
Popular
Obtener la aplicación
App Store
Google Play

Soporte: (55) 4170 8128 | soporte@advfn.mx

Al acceder a los servicios disponibles de ADVFN usted acepta quedar sujerto a los Términos y Condiciones

© 2024 ADVFN PLC - Todos los derechos reservados